Buradasınız

Anasayfa » Content

Benign Prosta t Hiperplazisinin Semptomatik Tedavisinde Doksazosin ve Terazosinin Etkinlik ve Yan Etki Karşılaştırması

Doxazosin Versus Terazosin : Efficacy And Side Effect in Treatment of Benign Prostate Hyperplazia

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Purpose : We compared effectiveness and side effects of doxazosin and terazosin based upon urodynamic parameters, in patients with infravesical obstructive complaints due to benign prostatic hyperplasia. Materials and Methods : Ninety patients were treated by doxazosin, terazosin or placebo, each groups containing 30 patients. The duration of the study was six months. Results : Maximal and mean urinary flow rates increased significantly (p<0.001) in the doxazosin and terazosin groups but there was no significant increase in the placebo group. In doxazosin and terazosin groups, other parameters such as duration of micturition, time to reach peak urinary flow and residual urine volume also improved, however, bladder capacity and prostatic volume did not show any significant change. When evaluated according to IPSS (International Prostate Symptom Score), clinical improvement of the irritative and obstructive prostatism symptoms was 63% in the doksazosin group, 66% in the terazosine group and 23% in the placebo group. Tolerable side effects occurred in 13% of the patients in the doksazosin group and 10% in the terazosin group. Conclusions : This study demonstrates that, selective alpha-1 blockers ; doxazosin and terazosin increase urinary flow rate and they are effective in alleviating the symptoms. Both drugs have similiar effectiveness and safety. Our results were similiar with the literature.
Bookmark/Search this post with
Abstract (Original Language): 
ııııııımıııımııımıııımııımııımıııımıııııiH Amaç: Benign prostat hiperplazisine bağlı infravezikal obstrüktif şikayetleri olan hastalarda doksazosin ve terazosini etkinlik ve yan etki yönünden ürodinamik parametreler eşliğinde karşılaştırmak istedik. Gereç ve Yöntem: 6 ay süreyle 90 hastanın 30'una doksazosin , 30'una terazosin, 30'una da plasebo verilerek plasebo kontrollü, çift merkezli bir çalışma yapıldı ve sonuçları değerlendirildi. Bulgular: Hem doksazosin hem terazosin grubunda maksimum ve ortalama akım hızı istatiksel olarak anlamlı bir artış gösterirken (p< 0.001) , plasebo grubundaki düzelmeler anlamlı bulunmadı. Her iki grupta da miksiyon süresi, maksimum akıma erişme süresi ve rezidüel volüm parametrelerinde anlamlı oranda düzelme görülürken, mesane kapasitesi ve prostat volüm değerlerinde değişiklik oluşmadı. İnfravezikal obstrüksiyona bağlı semptomların IPSS yöntemine göre doksazosin grubunda %63 , terazosin grubunda %65 , plasebo grubunda ise %23 oranında düzeldiği görüldü. Doksazosin grubunda yaklaşık %13 oranında , terazosin grubunda ise %10 oranında tolere edilebilir düzeyde yan etkiler oluştu. Sonuç: Bu çalışma selektif alfa-l adrenerjik reseptör blokerleri olan doksazosin ve terazosinin benign prostat hiperplazisi semptomlarının giderilmesinde aynı oranda etkili ve güvenilir olduğunu göstermiştir.Sonuçlarımız literatürle uyumludur.
FULL TEXT (PDF): 
PDF icon arastirmax-benign-prosta-t-hiperplazisinin-semptomatik-tedavisinde-doksazosin-terazosinin-etkinlik-yan-etki-karsilastirmasi.pdf
  • 1
11-14
  • Turkish

REFERENCES

References: 

1. Berry S.J. Coffey DS. Walsh PC, et al: The Development Of Human Benign Prostatic Hyperplasia With Age. J Urol, 132:474, 1984.
2. Mebust WK, Holtgrewe HL, Cockett ATK, et al: Transurethral prostatectomy:
immediate and postoperative complications. A cooperative study of 13 participating
institutions evaluating 3885 patients. J.Urol, 141:243, 1989.
3. De Campos Feire G: BPH: The basis of pharmacological treatment. Non-Surgical
Treatment of BPH (Fizpatrick JM, ed) London, Churchill Livingstone. 47, 1992.
4. Caine M: Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia.
Urol Clin North A, 17:641, 1990.
5. Abrams P.H., Shah P.J.R., Stone R., Choa R.G.: Bladder outflow obstruction treated with phenoxybenzamine, Br.J.Urol.: 54: 527-530 :1982.
6. Caine M., Perlberg S., Shapiro A.: Phenoxybenzamine for benign prostatic obstruction ;
Review of 200 cases : Urology 1981; 17:542-546.
7. Learmonth K.R.: A contrubition to the neurophysiology ofthe urinary bladder in man.
Brain 1931; 54: 147-176.
8. Boreham P.F., Braithwaite P., Milewski P., Pearson H.: Alpha-adrenergic blockers in
prostatism. Br.J. Surg. 1977, 64:756.
9. Gerstenberg T., Blaabjerg J., Nielsen M.L., Clausen S.: Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia. A urodynamic investigation. invest. Urol. 1980, 18:29.
10. Furuya S., Kumamoto Y., Yokoyama E. et al.; Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J.Urol. 1982, 128:836.
11. Chapple CR, Aubry ML, James S, et al: Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. Br J Urol, 63: 487,
1989.
12. Tsujii T, Azuma H, Yamaguchi T, et al: A possible role of decreased relaxation mediated by alpha-adrenoceptors in bladder outlet obstruction by benign prostatic hyperplasia. Br J
Pharmacol, 107:803, 1992.
13. Andersson KE, Fovaeus M, Hedlund H: Urogenital muscarinic receptors and drug
effects. Ann Clin Res, 20:356, 1988.
14. Lepor H, Tang R, Shapiro E, et al: Location of the alphal adrenoceptor subtypes in
human prostate. J Urol, 151: 381A, 1994.
15. Price DT, Schwinn DA, Lomasney JW, et al: Identification of an alphald adrenergic
receptor cDNA. Mol Pharmacol, 40: 876, 1991.
16. Breslin D, Fields DW, Chou TC, et al: Medical management of benign prostatic hyperplasia: A canine model comparing the in vivo efficacy of alphal adrenergic antagonists in the prostate. J Urol, 149: 395, 1993.
17. 17.Jangnest RA, Chapple CR: For the doxazosin study groups: Efficacy and safety the alpha-blocker doxazosin in the treatment of benign prostatic hyperplasia (analysis of 5
studies). Eur Urol 1993, 24: 319-326
18. 18.Fawzy A, Braun K, Lewis GP, Gaffney K, Ice K, Dias N: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients:A multicenter study.J.Urol
1995;154:105-109.
19. Lepor H, Auerbach S, Puras-Baez A, et al: A randomized, placebo controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic
hyperplasia. J.Urol, 148: 1467, 1992.
20. Di Silverio F: Use of terazosin in the medical treatment of benign prostatic hyperplasia:
experiences in Italy. Br J Urol, 70(Suppl 1): 22, 1992.
21. 21.Özbey I, Aksoy Y, Polat O : Effects of doxazosin in man with benign prostatic
hyperplasia : Int Urol Nephrol.1999 ; 31 (4):471-9.
22. 22.Samlı MM, Dinçel C.:Terazosin and doxazosin in the treatment of BPH : reslts of a randomized study with crossover in non-responders.:Urol Int.2004; 73 (2):125-9.
23. Kirby RS, Chapple CR.Christmas TJ : Doxazosin :minimal blood pressure effects in normotensive males. J.Urol 149 (suppl) :434A,1993.
24. 24.Lloyd SN, Buckley JF, Chilton CP : Terazosin in the treatment of benign prostatic hyperplasia.Br J Urol, 70(suppl 1):17, 1992.

Thank you for copying data from http://www.arastirmax.com